SCHEMBL4607159

SCHEMBL4607159

CCc1nc(C)c(C(=O)OC)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 2/20 0.36
MAPK1 P28482 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRA6 Q16445 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3027865 0.86 ALDH1A1 (0.50) LMNAL3MBTL1HPGDKDM4EALDH1A1
SCHEMBL24283654 0.81 LMNA (0.37) LMNANPSR1L3MBTL1HPGDMAPK1
SCHEMBL24283838 0.81 LMNA (0.37) LMNANPSR1L3MBTL1HPGDMAPK1
SCHEMBL2778487 0.79 TP53 (0.44) LMNATP53L3MBTL1ALDH1A1
SCHEMBL11051317 0.79 TP53 (0.40) TP53L3MBTL1MAPK1ALDH1A1
SCHEMBL24284346 0.77 NPSR1 (0.43) LMNANPSR1TP53L3MBTL1HPGD
SCHEMBL370540 0.74 NPSR1 (0.40) LMNANPSR1TP53L3MBTL1HPGD
SCHEMBL3829117 0.72 ALDH1A1 (0.51) LMNATP53L3MBTL1HPGDMAPK1
SCHEMBL5809049 0.72 ALDH1A1 (0.47) LMNANPSR1L3MBTL1HPGDMAPK1
SCHEMBL8901944 0.71 TP53 (0.34) TP53L3MBTL1HPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569927-B1 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-07-16 EP disclosed
US-7358268-B2 Imidazole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-15 US disclosed
EP-1569927-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP disclosed
EP-1479674-A1 Imidiazole-derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
US-20040171604-A1 Imidazole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-02 US disclosed
WO-2004050636-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 WO disclosed
EP-1426364-A1 Imidazole-derivatives as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171604-A1 Imidazole derivatives as factor Xa inhibitors TFPI, F11, TFPI2 LMNA 599/4885NPSR1 2722/4885TP53 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.